Efficacy of tiotropium bromide powder inhalant combined with azithromycin in the treatment of stable bronchiectasis
Objective:To investigate the efficacy of tiotropium bromide powder inhalation combined with azithromycin in the treatment of stable bronchiectasis.Methods:90 patients with stable bronchiectasis admitted to the hospital from June 2020 to June 2022 were selected as the study objects.The patients were divided into control group and observation group with 45 cases in each group.The control group was treated with azithromycin.Observation group was treated with tiotropium bromide powder inhalation on the basis of control group.The inflammatory indexes,lung function and adverse reactions of the two groups were analyzed and compared before and after 3 months of treatment.Results:Compared with before treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-17(IL-17)in 2 groups were decreased after 3 months of treatment,and the observation group was lower than the control group(P<0.05).Compared with before treatment,the 1s forced expiratory volume(FEV1)and the percentage of the first second forced expiratory volume to forced vital capacity(FEV1/FVC)of both groups were increased after 3 months of treatment,and the observation group was higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Tiotropium powder inhalation combined with azithromycin in the treatment of stable bronchiectasis can reduce inflammatory response and improve lung function,with high safety.
NETL
NSTL
万方数据
